

Note

Selective Synthesis of 2-substituted and 1,2-disubstituted Benzimidazoles Directly from Aromatic Diamines and Alcohols Catalyzed by Molecularly Defined Non-Phosphine Manganese (I) Complex.

KALICHARAN DAS, Avijit Mondal, and Dipankar Srimani

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.8b01316 • Publication Date (Web): 11 Jul 2018

Downloaded from <http://pubs.acs.org> on July 11, 2018

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.




Selective Synthesis of 2-substituted and 1,2-disubstituted Benzimidazoles Directly from Aromatic Diamines and Alcohols Catalyzed by Molecularly Defined Non-Phosphine Manganese (I) Complex.

Kalicharan Das, Avijit Mondal and Dipankar Srimani*

Department of Chemistry, Indian Institute of Technology-Guwahati, Kamrup, Assam 781039, India.

Supporting Information



ABSTRACT: Herein, we present a selective synthesis of 2-substituted and 1,2-disubstituted benzimidazoles by acceptorless dehydrogenative coupling of aromatic diamine with primary alcohols. The reaction is catalyzed by phosphine free tridentate NNS ligand derived manganese (I) complex.

Over the past few years, benzimidazoles and their derivatives have attracted significant attention due to their important biological as well as pharmacological properties.¹ Several pharmaceutically important compounds having benzimidazole core are known for their antiallergic,² antihistaminic,³ anti-ulcerative,⁴ antihypertensive⁵ and antipyretic properties.⁶ Furthermore, benzimidazole derivatives are also effective against HIV⁷ and human cytomegalovirus (HCMV).⁸ The classical approach to synthesize benzimidazoles is the condensation of *o*-phenylenediamine with carboxylic acids or carboxylic acid-derivatives under strong acidic conditions.⁹ Another widely used strategy involves the condensation 1,2-phenylenediamine with aldehyde/alcohol in the presence of different oxidizing agents.¹⁰ Several other different catalytic approaches to synthesize benzimidazoles are also reported.¹¹⁻¹⁴ However many of these method suffers either from the use of stoichiometric amount of oxidizing agents or expensive catalysts. Another major problem is the selectivity during the synthesis of 2-substituted and 1,2-disubstituted benzimidazoles. In recent times, acceptorless dehydrogenation strategies for synthesis of different heterocycles directly from alcohols¹⁵ are becoming more and more important, as alcohols can be readily obtained from renewable lignocellulose.¹⁶ Thus, the synthesis of benzimidazoles¹⁷ directly from primary alcohol and *o*-phenylenediamine has recently attracted much attention and most of these methodologies use precious noble metals and/or acceptors.¹⁸ One of the earliest example of such type of reaction was developed by Watanbe and coworkers.^{18a} The reaction is catalyzed by ruthenium complex at elevated temperature (215 °C). Recently, Kempe and coworkers developed an elegant method to synthesize 2-substituted benzimidazoles under relatively milder condition.^{18b} The reaction is catalyzed by iridium pincer complex and does not

involve any acceptor. Selective synthesis of 1,2-disubstituted imidazole from diamine and alcohol catalysed by Ir(III) complexes was also accomplished recently.^{18c}

The replacement of costly noble-metal catalyst by inexpensive environmentally benign earth-abundant metals is an important goal in homogenous catalysis. In the recent years, considerable efforts were made towards the development of several different de(hydrogenative) reaction methodologies using base metal complexes.¹⁹ Although manganese is less expensive abundant and nontoxic metal, the catalytic de(hydrogenative) reactions with manganese is still in the nascent stage. The (de)hydrogenative reactions catalyzed by Mn-pincer complexes became a very important topic in the area of catalysis after the seminal works published independently by the group of Milstein, Beller, Kempe and Kirchner in 2016.²⁰ Subsequent to these reports a significant number of intriguing transformations catalyzed by Mn-complexes have been developed.²¹

Very recently, the formation of 2-substituted benzimidazoles catalyzed by cobalt pincer²² complex has been reported by Milstein and co-workers. However, selective synthesis of both 2-substituted and 1,2-disubstituted benzimidazoles from 1,2-diamino benzene and alcohol using earth-abundant, nontoxic metal catalyst is highly desirable. To the best of our knowledge the synthesis of benzimidazoles directly from 1,2-diaminobenzene and alcohol catalyzed by manganese has not been reported. Herein, we describe a general and selective method to synthesize both 2-substituted and 1,2-disubstituted benzimidazoles from 1,2-diamino benzene and alcohol using non-phosphine-manganese complex. At the outset, we prepared new NNS-Manganese (I) complex (**1**) by refluxing 2-(ethylthio)-N





Figure 1. Synthesis of tridentate NNS ligand based manganese (I) complex and molecular structure of **1** with thermal ellipsoid 30% probability level. (all the hydrogens except N₂ and the counter ion are not shown for the clarity)

(pyridin-2-ylmethyl)ethanamine with MnBr(CO)₅ in THF. Single crystal suitable for X-ray diffraction was made by layering THF solution of the complex **1** with toluene. The crystal structure of **1** is more like octahedral geometry around Mn-center, which is formed by tridentate ligand and three carbonyl groups. The crystal structure reveals that both the N atoms and the S atom are *cis* to each other and the three carbonyls are *cis* to each other (Figure 1).


Table 1. Optimization of the reaction conditions for the synthesis of 1,2-disubstituted benzimidazole^{a, b}



Entry	Cat	Base (mmol)	Time (h)	Amine : Alcohol (mmol)	% Yield ^b
1	1	tBuOK (1.2)	20	0.5 : 1.5	63
2	1	tBuOK (1.2)	20	0.5 : 1.7	71
3	1	tBuOK (1.2)	24	0.5 : 2.0	71
4	1	tBuOK (1.4)	20	0.5 : 1.7	56
5	1	tBuOK (2.0)	24	0.5 : 1.7	56
6	1	tBuOK (1.0)	20	0.5 : 1.7	83
7	1	tBuOK (0.75)	20	0.5 : 1.7	42
8 ^c	1	tBuOK (1.0)	20	0.5 : 1.7	55
9 ^d	1	tBuOK (1.0)	24	0.5 : 1.7	-
10	----	tBuOK (1.0)	20	0.5 : 1.7	-
11	1	----	20	0.5 : 1.7	-
12	1	KOH (1.0)	20	0.5 : 1.7	61
13	1	K ₂ CO ₃ (1.0)	20	0.5 : 1.7	-
14	MnBr(CO) ₅	tBuOK (1.0)	20	0.5 : 1.7	-

^aReaction conditions: **2a** (0.5 mmol), **3b** (1.5-2.0 mmol), *t*BuOK (0.75-2.0 mmol), Cat **1** (0.05 mmol), under argon. ^bNMR yield using CH₃CN as internal standard. ^c0.025 mmol cat used. ^d80 °C


Table 2. Scope of the reaction to synthesize 1,2-disubstituted benzimidazole^{a, b}



^aReaction conditions: Diamine **2** (0.5 mmol), alcohol **3** (1.7 mmol), *t*BuOK (1 mmol), Cat **1** (0.05 mmol), 20 h, under argon, ^bIsolated yield, ^c44 h, ^d26 h


The catalytic applicability of complex **1** towards the synthesis of 1,2-disubstituted benzimidazole, directly from 1,2-phenylenediamines and alcohols has been investigated. To find out the optimum conditions, the reaction between 1,2-phenylenediamine and 4-methoxybenzylalcohol was studied under neat condition. It was found that the particular ratio of base and substrate and specific ratio of amine and alcohol is important for good yield of the desired products. Potassium tert-butoxide was found to be more effective base than KOH or K₂CO₃ (Table 1 entries 6, 12 and 13). MnBr(CO)₅ gave only trace amount of the desired product under the similar reaction conditions. The control experiments were also performed and it was observed that in the absence of catalyst, no desired product was obtained and similarly without the presence of base, complex **1** failed to give any desired product (Table 1 entries 10, 11).

Here, a wide range of 1-benzyl-2-aryl-1H-benzo[d]imidazole derivatives were also synthesized from 1,2-diaminobenzene and primary alcohol (Table 2). Differently substituted benzylic alcohols as well as 2-naphthalenemethanol reacted well with o-phenylenediamine to give good yield of the desired products. Moderate to good yield of the desired 1,2-disubstituted benzimidazoles were achieved when heterocyclic alcohols such as 2-pyridinemethanol, furfural or 2-thiophenemethanol have been employed as substrates. A small amount of bis N-alkylated

Table 3. Synthesis of 2-substituted benzimidazole ^{a, b}

^aReaction conditions: Diamine (1.0 mmol), alcohol (1.3 mmol), KOH (0.27 mmol), Cat **1** (0.05 mmol), 20 h, under air. ^bIsolated yield, ^c72 h


product of the *o*-phenylenediamine was also observed in some cases, which might be due to the hydrogenation of bis-imines formed *in-situ* during the reaction. Furthermore, 4,5-Dimethyl-1,2-phenylenediamine, 4,5-Dichloro-*o*-phenylenediamine and 3,4-diaminotoluene reacted smoothly under the optimized reaction condition. 3,4-diaminotoluene gave mixture of two isomeric 1-benzyl-2-aryl-1H-benzo[d]imidazole derivatives. It is important to note that synthesis of 2-aryl-1H-benzo[d]imidazole derivatives could also be achieved just by tuning the reaction conditions (Table 3).

Table 4. Synthesis of 1-benzyl-2-aryl-1H-benzo[d]imidazoles^{a, b}

^aReaction conditions: N-Benzyl-1,2-diaminobenzene (1.0 mmol), alcohol (1.3 mmol), KOH (0.27 mmol), Cat **1** (0.05 mmol), 20 h, under air. ^bIsolated yield.


Excellent yield of the desired products were obtained with the benzyl alcohols having both electron donating and electron withdrawing group in the aromatic ring. For example, 4-methylbenzyl alcohol and 4-methoxybenzyl alcohol gave 81% and 82% yield of the desired benzimidazole respectively, which is even higher than the yield reported by Ru^{18a} or cobalt catalyst.²² However, the reaction is slower with aliphatic alcohols. Thus, when 1-octanol was used as substrate, 35% of the 2-ethyl-1H-benzo[d]imidazole was obtained after 72 hours. To our delight, complex **1** also able to catalyse the dehydrogenative coupling of N-Benzyl-1,2-diaminobenzene (**6**) with different benzyl alcohols to afford 1-benzyl-2-aryl-1H-benzo[d]imidazole derivatives (**7**) in good yield (Table 4).

In addition, three possible mechanistic pathways are proposed which are depicted in the (Scheme 1). At first, the aldehyde was formed by the assistance of Mn-complex **1**. The diamine can react with the aldehyde **A** to form monoamine **B** which can further undergo nucleophilic addition to the imine carbon to form benzimidazoline intermediate **C**. This intermediate benzimidazoline **C** either undergoes oxidation leading to the formation of 2-substituted benzimidazole **5a** or reacts further with the aldehyde **A** to generate intermediate **D** which will finally transform to 1,2-disubstituted imidazole **4a** (Path II). There is also a possibility of N-alkylation of 2-substituted benzimidazole²³ by primary alcohol through borrowing hydrogen strategy, which will eventually transform **5a**, to **4a** (Path I). Furthermore, diamine also can lead to the formation of bis-imine **F** which undergoes rearrangement to afford 1,2-disubstituted benzimidazole (Path III).¹⁷ⁱ

Scheme 1. Plausible mechanistic pathway

Although the exact pathway is not fully clear at this point, yet we tried to shed light on the mechanism by controlling experiment. First of all, when 2-(4-methoxyphenyl)-1H-benzo[d]imidazole **5b** was treated with 4-methoxybenzyl alcohol **3a** in presence of Cat **1** and *t*BuOK, no N-alkylated product, 1-(4-methoxybenzyl)-2-(4-methoxyphenyl)-1H-benzo[d]imidazole **4b** was observed (Scheme 2). Thus, it is clear that the reaction is not following Path I. MS analysis of the crude reaction mixture of *o*-phenylenediamine and 4-methoxybenzyl alcohol after 2 h, showed peak which corresponds either to bisimine (**F**, Ar=

Scheme 2. Study of N-alkylation of 2-substituted benzimidazole By Cat 1



p-C₆H₄OMe) or 1,2 disubstituted benzimidazole **4b** (as the molecular weight of both the compound are same) while the ion peak corresponds to intermediate (**D**, Ar = p-C₆H₄OMe) was not observed. We have also isolated small amount bis-amine **H** during the synthesis of 1-benzyl-2-aryl-1H-benzo[d]imidazole derivatives which finally validate the involvement of bis-imine intermediate **F** and formation of 1,2 disubstituted imidazole derivatives via Path III.

In Summary, we have synthesized a new tridentate NNS-ligand based manganese (I) complex, which catalyzes the dehydrogenative coupling of diamine and primary alcohol to synthesize a wide range of benzimidazole derivatives. The main advantage of this methodology is 3-fold: selectively 2-substituted and 1,2 di-substituted benzimidazoles are synthesized using a single catalyst just by tuning the reaction conditions, the reactions are catalyzed by earth abundant metal and catalytic reactions are performed under phosphine free condition.

EXPERIMENTAL SECTION

General Considerations: Unless otherwise mentioned, all the chemicals were purchased from common commercial sources and used as received. All solvents were dried by using standard procedure. The preparation of catalyst was carried out under argon atmosphere with freshly distilled dry THF. All catalytic reactions were carried out with air and/or under argon atmosphere using dried glassware and standard syringe/septa techniques. DRX-400 Varian spectrometer and Bruker Avance III 600 and 400 spectrometers were used to record ¹H and ¹³C NMR spectra using CDCl₃ and DMSO-d₆ as solvent and TMS as an internal standard. Chemical shifts (δ) are reported in ppm and spin-spin coupling constant (J) are expressed in Hz, and other data are reported as follows: s = singlet, d = doublet, t = triplet, m = multiplet, q = quartet, and br s = broad singlet. X-ray crystallographic data were collected using Agilent Super Nova (Single source at offset, Eos) diffractometer. FTIR were collected on PerkinElmer IR spectrometer. Q-ToF ESI-MS instrument (model HAB 273) was used for recording mass spectra. SRL silica gel (100-200 mesh) were used for column chromatography.

Synthesis and characterization of NNS-Mn-complex 1: Ligand²⁴ [(PyCH₂)HN(CH₂CH₂SEt)] (0.302g, 1.54 mmol) was taken in 4 mL dry THF and was added dropwise to the orange-yellow suspension of [MnBr(CO)₅] (0.423g, 1.54 mmol) in 8 mL degassed dry THF. Then, the suspension was refluxed for overnight under argon atmosphere. After cooling it down to the room temperature, the solvent was evaporated to obtain the residue, which was further washed with hexane and dried under vacuum to get yellow solid of Mn-complex **1** (yield 0.610g, 95%). The single crystal was grown by slow diffusion of toluene in the THF solution of the complex. ¹H NMR (600 MHz, CDCl₃) δ 8.69 (s, 1H), 8.26 (br s, 1H), 7.87 (br s, 1H), 7.71 (br

s, 1H), 7.40 (br s, 1H), 4.81 (br s, 1H), 4.58 (br s, 1H), 3.39-3.35 (m, 2H), 2.98-2.87 (m, 2H), 2.05 (br s, 2H), 1.45 (s, 3H); ²⁵ ¹³C NMR (150 MHz, CDCl₃) δ 218.92, 216.57, 161.90, 152.64, 139.58, 125.25, 122.70, 60.41, 54.57, 33.07, 31.85, 13.42. IR (cm⁻¹): 3059, 2920, 2875, 2030, 1946, 1920, 1609, 1462, 1286, 1196, 1083, 949, 910, 821, 769, 689, 637. HRMS (ESI) calcd for C₁₃H₁₆MnN₂O₃S [M]⁺: 335.0262; found, 335.0263.

General experimental procedure for the synthesis of 1,2-disubstituted benzimidazoles: A mixture of *o*-phenylenediamine (0.5 mmol), primary alcohol (1.7 mmol), KO^tBu (1.0 mmol) and complex **1** (0.05 mmol) was stirred at 140 °C for the specified time under solvent free condition in an open system under argon. Then the reaction mixture was cooled to room temperature and was diluted with chloroform. Then it was filtered through celite and the filtrate was concentrated under vacuum. The residue obtained was further purified by column chromatography on silica gel using 10%-30 % ethyl acetate in hexane as an eluent.

General experimental procedure for the synthesis of 2-substituted benzimidazoles: A mixture of 1,2-diaminobenzene (1.0 mmol), primary alcohol (1.3 mmol), KOH (0.27 mmol) and catalyst **1** (0.05 mmol) was stirred under neat condition at 140 °C for 20 h in open air. After cooling, MeOH was added to dilute the mixture and filtered through celite. The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography using 10% - 30 % ethyl acetate in hexane as an eluent to get pure compound.

General experimental procedure for the synthesis of 1-benzyl-2-aryl-1H-benzo[d]imidazoles: A mixture of N-Benzyl-1,2-diaminobenzene (1.0 mmol), primary alcohol (1.3 mmol), KOH (0.27 mmol) and catalyst **1** (0.05 mmol) was stirred under neat condition at 140 °C for 20 h in open air. After cooling, CHCl₃ was added to dilute the mixture and then it was filtered through celite. The filtrate was concentrated under vacuum and the residue was purified by silica gel column chromatography using 10% -30 % ethyl acetate in hexane as an eluent to get pure compound.

1-Benzyl-2-phenyl-1H-benzo[d]imidazole (4a).^{17a} White solid, (0.113mg, 79% yield). ¹H NMR (600 MHz, CDCl₃) δ 7.80 (d, J = 8.04 Hz, 1H), 7.62-7.60 (m, 2H), 7.40- 7.36 (m, 3H), 7.27-7.21 (m, 4H), 7.18-7.13 (m, 2H), 7.03 (d, J = 7.02 Hz, 2H), 5.39 (s, 2H); ¹³C NMR (150 MHz, CDCl₃) δ 154.3, 143.3, 136.5, 136.2, 130.2, 130.0, 129.4, 129.2, 128.9, 127.9, 126.1, 123.2, 122.8, 120.1, 110.7, 48.5.

1-(4-methoxybenzyl)-2-(4-methoxyphenyl)-1H-benzo[d]imidazole (4b).^{17a} White solid, (0.129mg, 83% yield). ¹H NMR (600 MHz, CDCl₃) δ 7.75 (d, J = 7.98 Hz, 1H), 7.55 (d, J = 8.7 Hz, 2H), 7.22-7.18 (m, 1H), 7.15-7.12 (m, 2H), 6.94 (d, J = 8.52 Hz, 2H), 6.88 (d, J = 8.7 Hz, 2H), 6.76 (d, J = 8.7 Hz, 2H), 5.29 (s, 2H), 3.75 (s, 3H), 3.69 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 161.0, 159.2, 154.2, 143.2, 136.2, 130.8, 128.6, 127.3, 122.8, 122.6, 122.5, 119.8, 114.5, 114.3, 110.5, 55.5, 55.4, 48.0.

1-(3-methoxybenzyl)-2-(3-methoxyphenyl)-1H-benzo[d]imidazole (4c).^{18c} White solid, (0.156mg, 91% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.79 (d, J = 5.32Hz, 1H), 7.29-7.23 (m, 2H), 7.19-7.16 (m, 5H), 6.95-6.96 (m, 1H), 6.75 (dd, J = 7.2 Hz, 1.14 Hz, 1H), 6.62 (d, J = 5.12 Hz, 1H), 6.58 (s, 1H), 5.36 (s, 2H), 3.66 (s, 3H), 3.65 (s, 3H); ¹³C NMR (100 MHz, CDCl₃); δ 160.3, 159.8, 154.1, 143.1, 138.3, 136.3, 131.3,

130.3, 130.0, 123.2, 122.8, 121.5, 120.1, 118.3, 116.7, 114.1, 113.0, 112.0, 110.6, 55.4, 55.3, 48.4.

2-(naphthalen-2-yl)-1-(naphthalen-2-ylmethyl)-1H-benzo[d]imidazole (4d).^{17a} White solid, (0.155mg, 81% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.13 (s, 1H), 7.88-7.75 (m, 6H), 7.67-7.63 (m, 2H), 7.49-7.39 (m, 5H), 7.30-7.16 (m, 4H), 5.59 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 154.4, 143.4, 136.5, 134.1, 133.8, 133.5, 133.02, 132.9, 129.4, 129.2, 128.7, 128.7, 128.0, 127.9, 127.4, 126.8, 126.8, 126.4, 126.2, 124.9, 124.0, 123.4, 123.0, 120.2, 110.7, 48.9.

1-(4-methylbenzyl)-2-(p-tolyl)-1H-benzo[d]imidazole (4e).^{17a} White solid, (0.126mg, 81% yield). ¹H NMR (600 MHz, CDCl₃) δ 7.78 (d, *J* = 8.04 Hz, 1H), 7.51 (d, *J* = 8.16 Hz, 2H), 7.23-7.21 (m, 1H), 7.19-7.17 (m, 2H), 7.16-7.11 (m, 2H), 7.06 (d, *J* = 7.92 Hz, 2H), 6.92 (d, *J* = 8.04 Hz, 2H), 5.33 (s, 2H), 2.33 (s, 3H), 2.26 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 154.5, 143.3, 140.1, 137.5, 136.2, 133.6, 129.8, 129.6, 129.3, 127.3, 126.0, 122.9, 122.7, 119.9, 110.6, 48.3, 21.6, 21.2.

1-(3-phenoxybenzyl)-2-(3-phenoxybenzyl)-1H-benzo[d]imidazole (4f).²⁶ Brown liquid, (0.186mg, 80% yield). ¹H NMR (600 MHz, CDCl₃) δ 7.75 (d, *J* = 7.98 Hz, 1H), 7.34-7.29 (m, 2H), 7.24-7.21 (m, 6H), 7.19-7.16 (m, 1H), 7.14-7.12 (m, 2H), 7.05-7.0 (m, 3H), 6.92 (dd, *J* = 8.58 Hz, 1.02 Hz, 2H), 6.86 (dd, *J* = 8.46 Hz, 1.02 Hz, 2H), 6.80 (d, *J* = 6.72 Hz, 1H), 6.64 (d, *J* = 6.84 Hz, 2H); 5.31 (s, 2H); ¹³C NMR (150 MHz, CDCl₃) δ 158.1, 157.9, 156.6, 153.5, 143.1, 138.3, 136.0, 131.7, 130.5, 130.3, 130.0, 129.9, 129.8, 123.9, 123.9, 123.8, 123.4, 122.9, 120.6, 120.2, 120.2, 119.4, 119.3, 119.2, 117.9, 116.3, 110.6, 48.2.

2-(thiophen-2-yl)-1-(thiophen-2-ylmethyl)-1H-benzo[d]imidazole (4g).^{17a} White solid, (0.121mg, 81% yield). ¹H NMR (600 MHz, CDCl₃) δ 7.76 (d, *J* = 7.08 Hz, 1H), 7.45 (dd, *J* = 5.37 Hz, 1.02 Hz, 1H), 7.40 (dd, *J* = 3.75 Hz, 1.02 Hz, 1H), 7.31-7.29 (m, 1H), 7.25-7.19 (m, 2H), 7.17 (dd, *J* = 5.1 Hz, 1.14 Hz, 1H), 7.08-7.06 (m, 1H), 6.88-6.87 (m, 1H), 6.80-6.79 (m, 1H), 5.63 (s, 2H); ¹³C NMR (150 MHz, CDCl₃) δ 147.7, 143.1, 138.9, 136.0, 132.0, 129.1, 128.1, 128.1, 127.4, 125.6, 125.5, 123.4, 123.1, 120.1, 110.0, 44.2.

2-(pyridin-2-yl)-1-(pyridin-2-ylmethyl)-1H-benzo[d]imidazole (4h).^{17a} White solid, (0.113mg, 79% yield). ¹H NMR (CDCl₃, 400 MHz) δ 8.50 (t, *J* = 5.02 Hz, 2H), 8.39 (d, *J* = 8.0 Hz, 1H), 7.80-7.74 (m, 2H), 7.42-7.38 (dt, *J* = 7.74, 1.68 Hz, 1H), 7.29 (d, *J* = 7.92 Hz, 1H), 7.25-7.16 (m, 3H), 7.07-7.04 (m, 1H), 6.82 (d, *J* = 7.92 Hz, 1H), 6.22 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 157.6, 150.5, 150.0, 149.3, 148.8, 142.8, 137.0, 137.0, 136.9, 124.7, 124.0, 123.8, 123.1, 122.4, 121.1, 120.2, 110.9, 51.2.

2-(furan-2-yl)-1-(furan-2-ylmethyl)-1H-benzo[d]imidazole (4i).^{17a} White solid, (0.089mg, 67% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.72-7.69 (m, 1H), 7.57 (d, *J* = 0.96 Hz, 1H), 7.44-7.40 (m, 1H), 7.25-7.18 (m, 3H), 7.14 (d, *J* = 3.44 Hz, 1H), 6.54-6.53 (m, 1H), 6.21-6.16 (m, 2H), 5.57 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 149.7, 145.5, 144.1, 144.0, 143.1, 142.8, 135.6, 123.4, 123.1, 119.9, 113.1, 112.2, 110.7, 110.1, 108.5, 41.8.

1-(4-chlorobenzyl)-2-(4-chlorobenzyl)-1H-benzo[d]imidazole (4J).^{17a} White solid, (0.137mg, 78% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.79 (d, *J* = 7.92 Hz, 1H), 7.51 (d, *J* = 8.52 Hz, 2H), 7.37 (d, *J* = 8.52 Hz, 2H), 7.30 - 7.22 (m, 3H), 7.20-7.12 (m, 2H), 6.95 (d, *J* = 8.44 Hz, 2H), 5.33 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 153.0, 143.2, 136.5, 136.1, 134.8, 134.0,

130.6, 129.5, 129.3, 128.5, 127.4, 123.6, 123.2, 120.3, 110.4, 47.9.

1-(4-chlorobenzyl)-2-(4-chlorophenyl)-5,6-dimethyl-1H-benzo[d]imidazole (4k).²⁷ White solid, (0.145mg, 76% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.61 (s, 1H), 7.56 (d, *J* = 8.48 Hz, 2H), 7.41 (d, *J* = 8.48 Hz, 2H), 7.31 (d, *J* = 8.40 Hz, 2H), 7.01 (d, *J* = 8.24 Hz, 2H), 6.95 (s, 1H), 5.34 (s, 2H), 2.39 (s, 3H), 2.34 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 152.2, 141.9, 136.2, 135.1, 134.7, 133.9, 132.9, 132.2, 130.5, 129.5, 129.2, 128.8, 127.3, 120.3, 110.5, 47.8, 20.7, 20.5.

1-benzyl-5,6-dimethyl-2-phenyl-1H-benzo[d]imidazole (4l).²⁸ White solid, (0.121mg, 77% yield). ¹H NMR (600 MHz, CDCl₃) δ 7.67-7.65 (m, 2H), 7.63 (s, 1H), 7.45-7.40 (m, 3H), 7.35-7.28 (m, 3H), 7.10 (d, *J* = 7.08 Hz, 2H), 6.97 (s, 1H), 5.41 (s, 2H), 2.39 (s, 3H), 2.32 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 153.5, 141.9, 136.8, 134.8, 132.4, 131.7, 130.4, 129.8, 129.3, 129.2, 128.8, 127.8, 126.0, 120.1, 110.7, 48.4, 20.7, 20.5.

5,6-Dimethyl-1-(4-methylbenzyl)-2-(4-methylphenyl)-1H-benzimidazole (4m).²⁷ White solid, (0.122mg, 72% yield). ¹H NMR (600 MHz, CDCl₃) δ 7.61 (s, 1H), 7.55 (d, *J* = 8.04 Hz, 2H), 7.22 (d, *J* = 7.92 Hz, 2H), 7.13 (d, *J* = 7.86 Hz, 2H), 6.99 (d, *J* = 7.92 Hz, 2H), 6.96 (s, 1H), 5.36 (s, 2H), 2.39 (s, 3H), 2.38 (s, 3H), 2.34 (s, 3H), 2.32 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 153.6, 141.8, 139.8, 137.4, 134.8, 133.9, 132.1, 131.5, 129.8, 129.5, 129.2, 127.5, 125.9, 120.0, 110.7, 48.2, 21.5, 21.2, 20.7, 20.5.

5,6-dimethyl-2-(naphthalen-2-yl)-1-(naphthalen-2-ylmethyl)-1H-benzo[d]imidazole (4n).²⁸ White solid, (0.187mg, 91% yield). ¹H NMR (CDCl₃, 600 MHz) δ 8.18 (s, 1H), 7.90-7.82 (m, 5H), 7.74-7.70 (m, 3H), 7.57 (s, 1H), 7.53-7.46 (m, 4H), 7.33 (d, *J* = 8.46 Hz, 1H), 7.05 (s, 1H), 5.63 (s, 2H), 2.42 (s, 3H), 2.33 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 153.6, 142.1, 135.1, 134.4, 133.7, 133.6, 133.0, 132.9, 132.6, 131.9, 129.2, 129.1, 128.7, 128.6, 128.1, 127.9, 127.9, 127.7, 127.2, 126.7, 126.7, 126.3, 126.3, 124.7, 124.0, 120.2, 110.7, 48.8, 20.8, 20.5.

5,6-dimethyl-2-(pyridin-2-yl)-1-(pyridin-2-ylmethyl)-1H-benzo[d]imidazole (4o).²⁹ Orange solid, (0.137mg, 87% yield). ¹H NMR (600 MHz, CDCl₃) δ 8.59 (d, *J* = 4.56 Hz, 1H), 8.53 (d, *J* = 4.56 Hz, 1H), 8.44 (d, *J* = 8.04 Hz, 1H), 7.81 (dt, *J* = 7.83 Hz, 1.56 Hz, 1H), 7.62 (s, 1H), 7.47 (dt, *J* = 7.71 Hz, 1.68 Hz, 1H), 7.27-7.25 (m, 1H), 7.15-7.13 (m, 1H), 7.11 (s, 1H), 6.83 (d, *J* = 7.92 Hz, 1H), 6.25 (s, 2H), 2.38 (s, 3H), 2.33 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 157.8, 150.6, 149.2, 149.2, 148.7, 141.4, 137.0, 136.9, 135.5, 133.3, 132.1, 124.4, 123.7, 122.3, 120.9, 120.1, 110.8, 51.2, 20.8, 20.5.

5,6-dichloro-1-(4-methoxybenzyl)-2-(4-methoxyphenyl)-1H-benzo[d]imidazole (4p).^{17d} White solid, (0.122mg, 64% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.89 (s, 1H), 7.62 (d, *J* = 8.64 Hz, 2H), 7.28 (s, 1H), 6.99 (t, *J* = 8.24 Hz, 4H), 6.88 (d, *J* = 8.52 Hz, 2H), 5.34 (s, 2H), 3.86 (s, 3H), 3.80 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 161.4, 159.5, 156.2, 142.7, 135.5, 130.8, 127.6, 127.2, 126.7, 126.7, 121.7, 121.0, 114.8, 114.5, 111.9, 55.6, 55.5, 48.2.

5-methyl-1-(4-methylbenzyl)-2-(p-tolyl)-1H-benzo[d]imidazole & 6-methyl-1-(4-methylbenzyl)-2-(p-tolyl)-1H-benzo[d]imidazole (4q & 4q').^{17f} White solid, (0.127mg, 78% yield). ¹H NMR (600 MHz, CDCl₃) δ 7.72 (d, *J* = 8.16 Hz, 1H), 7.63 (s, 1H), 7.58-7.55 (m, 4H), 7.25-7.22 (m, 4H), 7.15-7.11 (m, 5H), 7.07-7.02 (m, 2H), 7.00-6.98 (m, 5H), 5.36 (s, 4H), 2.48 (s, 3H), 2.42 (s, 3H), 2.39 (s, 3H), 2.39 (s,

3H), 2.34 (s, 3H), 2.33 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 154.3, 154.0, 143.5, 141.3, 140.0, 139.9, 137.5, 137.4, 136.5, 134.3, 133.7, 133.7, 133.0, 132.3, 129.8, 129.8, 129.5, 129.5, 129.2, 129.2, 127.4, 126.0, 125.9, 124.4, 124.3, 119.7, 119.4, 110.4, 110.1, 48.3, 48.1, 22.0, 21.7, 21.5, 21.5, 21.2, 21.2.

5-methyl-2-(thiophen-2-yl)-1-(thiophen-2-ylmethyl)-1H-benzo[d]imidazole & 6-methyl-2-(thiophen-2-yl)-1-(thiophen-2-ylmethyl)-1H-benzo[d]imidazole (4r & 4r').^{17f} Yellow solid, (0.091mg, 59% yield). ¹H NMR (600 MHz, CDCl₃) δ 7.70 (d, *J* = 8.22, 1H), 7.61 (s, 1H), 7.51-7.49 (m, 2H), 7.45-7.42 (m, 2H), 7.26-7.23 (m, 3H), 7.15-7.09 (m, 5H), 6.96-6.93 (m, 2H), 6.86-6.85 (m, 2H), 5.67 (s, 2H), 5.66 (s, 2H), 2.48 (s, 3H), 2.47 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 147.6, 147.2, 143.4, 141.2, 139.1, 139.1, 136.2, 134.1, 133.6, 132.9, 132.1, 132.1, 128.9, 128.8, 128.0, 128.0, 127.8, 127.4, 127.3, 125.5, 125.5, 125.4, 124.9, 124.8, 119.8, 119.5, 109.8, 109.5, 44.2, 44.1, 22.1, 21.7.

1-benzyl-2-(p-tolyl)-1H-benzo[d]imidazole (7a).^{17b} White solid, (0.201mg, 67% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.78 (d, *J* = 8.0 Hz, 1H), 7.49 (d, *J* = 8.08 Hz, 2H), 7.25-7.19 (m, 4H), 7.16 (d, *J* = 8.0 Hz, 2H), 7.13-7.09 (m, 2H), 7.01 (d, *J* = 6.84 Hz, 2H), 5.35 (s, 2H), 2.31 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 154.4, 143.3, 140.1, 136.6, 136.2, 129.5, 129.2, 129.1, 127.8, 127.2, 126.1, 123.0, 122.7, 120.0, 110.5, 48.5, 21.5.

1-benzyl-2-(4-methoxyphenyl)-1H-benzo[d]imidazole (7b).^{17b} White solid, (0.219mg, 70% yield). ¹H NMR (600 MHz, CDCl₃) δ 7.86 (d, *J* = 8.04 Hz, 1H), 7.63 (d, *J* = 8.82 Hz, 2H), 7.34-7.28 (m, 4H), 7.23-7.18 (m, 2H), 7.11 (d, *J* = 7.38 Hz, 2H), 6.96 (d, *J* = 8.76 Hz, 2H), 5.43 (s, 2H), 3.83 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 161.0, 154.2, 143.2, 136.6, 136.2, 130.7, 129.1, 127.8, 126.0, 122.8, 122.6, 122.4, 119.8, 114.3, 110.5, 55.4, 48.4.

1-benzyl-2-(4-fluorophenyl)-1H-benzo[d]imidazole (7c).^{17b} White solid, (0.184mg, 61% yield). ¹H NMR (600 MHz, CDCl₃) δ 7.86 (d, *J* = 8.04 Hz, 1H), 7.68-7.65 (m, 2H), 7.35-7.31 (m, 4H), 7.26-7.22 (m, 2H), 7.14 (t, *J* = 8.58 Hz, 2H), 7.09 (d, *J* = 7.2, 2H), 5.43 (s, 2H); ¹³C NMR (150 MHz, CDCl₃) δ 163.8 (d, *J* = 249 Hz), 153.3, 143.1, 136.3, 136.2, 131.4, 131.3, 129.3, 128.0, 126.3 (d, *J* = 3 Hz), 126.0, 123.1 (d, *J* = 55.5 Hz), 120.1, 116.1 (d, *J* = 21 Hz), 110.6, 48.4.

1-benzyl-2-(4-chlorophenyl)-1H-benzo[d]imidazole (7d).^{17b} White solid, (0.202mg, 64% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.79 (d, *J* = 7.96 Hz, 1H), 7.55 (d, *J* = 8.56 Hz, 2H), 7.35 (d, *J* = 8.56 Hz, 2H), 7.29-7.23 (m, 4H), 7.20-7.15 (m, 2H), 7.01 (d, *J* = 6.52 Hz, 2H), 5.36 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 153.1, 143.2, 136.3, 136.3, 136.3, 130.7, 129.3, 129.2, 128.7, 128.1, 126.0, 123.4, 123.0, 120.2, 110.6, 48.5.

1-benzyl-2-(4-bromophenyl)-1H-benzo[d]imidazole (7e).^{17b} White solid, (0.240mg, 66% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.86 (d, *J* = 7.96 Hz, 1H), 7.59-7.53 (m, 4H), 7.36-7.30 (m, 4H), 7.27-7.21 (2H), 7.08 (d, *J* = 6.52 Hz, 2H), 5.42 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 153.1, 143.2, 136.3, 132.1, 130.8, 129.3, 129.1, 128.0, 126.0, 124.6, 123.5, 123.0, 120.2, 110.6, 48.5.

1-benzyl-2-(pyridin-2-yl)-1H-benzo[d]imidazole (7f).³⁰ White solid, (0.226mg, 79% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.50 (d, *J* = 4.72 Hz, 1H), 8.33 (d, *J* = 8.0 Hz, 1H), 7.77 (d, *J* = 8.08 Hz, 1H), 7.69 (t, *J* = 7.92 Hz, 1H), 7.25-7.05 (m, 9H), 6.08 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 150.6,

150.0, 148.7, 142.8, 137.5, 136.9, 136.9, 128.6, 127.4, 126.9, 124.7, 123.9, 123.6, 122.9, 120.2, 110.8, 49.0.

2-phenyl-1H-benzo[d]imidazole (5a).^{17c} Pale yellow solid, (0.149mg, 77% yield). ¹H NMR (600 MHz, DMSO-*d*₆) δ 12.95 (br s, 1H), 8.19 (d, *J* = 7.14 Hz, 2H), 7.67 (d, *J* = 6.96 Hz, 1H), 7.57-7.54 (m, 3H), 7.50-7.48 (m, 1H), 7.23-7.19 (m, 2H), ¹³C NMR (150 MHz, DMSO-*d*₆) δ 151.3, 143.8, 135.0, 130.2, 129.9, 129.0, 126.5, 122.6, 121.8, 118.9, 111.4.

2-(4-methoxyphenyl)-1H-benzo[d]imidazole (5b).^{17c} White solid, (0.184mg, 82% yield). ¹H NMR (600 MHz, DMSO-*d*₆) δ 12.76 (s, 1H), 8.11 (d, *J* = 8.76 Hz, 2H), 7.61 (d, *J* = 7.5 Hz, 1H), 7.49 (d, *J* = 7.5 Hz, 1H), 7.19 - 7.14 (m, 2H), 7.11 (d, *J* = 8.76 Hz, 2H), 3.84 (s, 3H); ¹³C NMR (150 MHz, DMSO-*d*₆) δ 160.6, 151.4, 143.9, 135.0, 128.1, 122.7, 122.2, 121.5, 118.5, 114.4, 111.1, 55.4.

2-(3-methoxyphenyl)-1H-benzo[d]imidazole (5c).^{17c} White solid, (0.189mg, 85% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.90 (s, 1H), 7.77-7.75 (m, 2H), 7.67 (d, *J* = 7.44 Hz, 1H), 7.53 (d, *J* = 7.36 Hz, 1H), 7.46 (t, *J* = 7.6 Hz, 1H), 7.24-7.17 (m, 2H), 7.07-7.05 (m, 1H), 3.86 (s, 3H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 159.7, 151.1, 143.7, 135.0, 131.5, 130.1, 122.6, 121.7, 118.9, 118.8, 115.9, 111.4, 111.3, 55.3.

2-(naphthalen-2-yl)-1H-benzo[d]imidazole (5d).^{17c} Yellow solid, (0.179mg, 73% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.08 (s, 1H), 8.75 (s, 1H), 8.32 (d, *J* = 8.04 Hz, 1H), 8.09-7.99 (m, 3H), 7.70 (d, *J* = 6.64 Hz, 1H), 7.61-7.59 (m, 3H), 7.23 (s, 2H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 151.3, 143.9, 135.2, 133.5, 132.8, 128.6, 128.5, 127.8, 127.62, 127.1, 126.9, 125.8, 124.0, 122.7, 121.8, 118.9, 111.4.

2-(p-tolyl)-1H-benzo[d]imidazole (5e).^{17c} White solid, (0.169mg, 81% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.82 (s, 1H), 8.07 (d, *J* = 8.12 Hz, 2H), 7.64 (d, *J* = 6.12 Hz, 1H), 7.51 (d, *J* = 6.24 Hz, 1H), 7.35 (d, *J* = 8.0 Hz, 2H), 7.18 (d, *J* = 3.76 Hz, 2H), 2.38 (s, 3H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 151.4, 143.8, 139.6, 135.0, 129.5, 127.5, 126.4, 122.3, 121.6, 118.7, 111.2, 21.0.

2-(3-phenoxyphenyl)-1H-benzo[d]imidazole (5f).³¹ Yellow solid, (0.246mg, 86% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.94 (s, 1H), 7.96 (d, *J* = 7.72 Hz, 1H), 7.81 (s, 1H), 7.65 (d, *J* = 7.6 Hz, 1H), 7.57 (t, *J* = 7.96 Hz, 1H), 7.52 (d, *J* = 7.56 Hz, 1H), 7.45 (t, *J* = 8.04 Hz, 2H), 7.24-7.11 (m, 6H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 157.4, 156.3, 150.5, 143.6, 135.0, 132.0, 130.8, 130.2, 123.9, 122.7, 121.8, 121.4, 120.0, 119.0, 119.0, 116.0, 111.4.

2-(thiophen-2-yl)-1H-benzo[d]imidazole (5g).^{17c} Yellow solid, (0.150mg, 75% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.94 (s, 1H), 7.83 (d, *J* = 3.6 Hz, 1H), 7.72 (d, *J* = 4.92 Hz, 1H), 7.55 (s, 2H), 7.24-7.18 (m, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 147.0, 133.7, 128.8, 128.3, 126.7, 122.6, 122.5, 121.9, 118.5, 111.3, 111.1.

2-(pyridin-2-yl)-1H-benzo[d]imidazole (5h).^{17c} Yellow solid, (0.176mg, 90% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.10 (s, 1H), 8.72 (d, *J* = 4.68 Hz, 1H), 8.33 (d, *J* = 7.88 Hz, 1H), 7.99 (dt, *J* = 7.76 Hz, 1.48 Hz, 1H), 7.70 (d, *J* = 7.6 Hz, 1H), 7.56-7.50 (m, 2H), 7.26-7.19 (m, 2H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 150.8, 149.4, 148.5, 143.9, 137.6, 134.9, 124.7, 123.2, 121.9, 121.4, 119.3, 112.1.

2-(4-bromophenyl)-1H-benzo[d]imidazole (5i).^{17c} Yellow solid, (0.219mg, 80% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.99 (s, 1H), 8.12 (d, *J* = 8.48 Hz, 2H), 7.76 (d, *J* = 8.48 Hz, 2H), 7.67 (d, *J* = 6.96 Hz, 1H), 7.53 (d, *J* = 6.84 Hz, 1H),

7.22 (s, 2H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 150.2, 143.7, 135.0, 132.0, 129.4, 128.4, 123.3, 122.8, 121.9, 119.0, 111.4.

2-(4-chlorophenyl)-1H-benzo[d]imidazole (5J).^{17c}

White solid, (0.187mg, 82% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.99 (s, 1H), 8.19 (d, *J* = 8.4 Hz, 2H), 7.62 (d, *J* = 8.56 Hz, 4H), 7.23-7.20 (m, 2H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 150.2, 143.7, 134.6, 129.1, 129.1, 128.2, 122.7, 122.1, 119.0, 111.5.

2-(4-fluorophenyl)-1H-benzo[d]imidazole (5k).^{17c} Yellow solid, (0.151mg, 71% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.92 (s, 1H), 8.25-7.21 (m, 2H), 7.67 (d, *J* = 7.24 Hz, 1H), 7.53 (d, *J* = 7.28 Hz, 1H), 7.40 (t, *J* = 8.88 Hz, 2H), 7.24-7.17 (m, 2H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 162.6 (d, *J* = 246 Hz), 150.4, 143.8, 135.0, 128.7 (d, *J* = 9 Hz), 126.8 (d, *J* = 3 Hz), 122.6, 121.7, 118.9, 116.0 (d, *J* = 22 Hz), 111.3.

2-(2,5-difluorophenyl)-1H-benzo[d]imidazole (5l).^{17f}

Orange liquid, (0.143mg, 62% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.70 (s, 1H), 8.00-7.96 (m, 1H), 7.66 (s, 2H), 7.54-7.48 (m, 1H), 7.44-7.39 (m, 1H), 7.26-7.24 (m, 2H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 158.3 (dd, *J* = 239 Hz, 2 Hz), 155.9 (d, *J* = 245 Hz, 2 Hz), 145.3 (t, 3 Hz), 122.8-122.3 (m), 119.5 (dd, *J* = 14.5, 9 Hz), 118.7, 118.6, 118.6, 118.5, 118.5, 118.4, 118.3, 118.2, 115.8 (dd, *J* = 23 Hz, 3 Hz).

5-methyl-2-(p-tolyl)-1H-benzo[d]imidazole (5m).³²

White solid, (0.162mg, 74% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.99 (d, *J* = 8.08 Hz, 2H), 7.48 (d, *J* = 7.56 Hz, 1H), 7.34 (s, 1H), 7.17 (d, *J* = 8.0 Hz, 2H), 7.03 (d, *J* = 8.24 Hz, 1H), 2.42 (s, 3H), 2.33 (s, 3H); ¹³C NMR (150 MHz, DMSO-*d*₆) δ 151.2, 139.5, 131.3, 129.6, 127.6, 126.5, 126.4, 123.5, 117.9, 111.3, 21.4, 21.1.

2-(4-chlorophenyl)-5-methyl-1H-benzo[d]imidazole (5n).³²

White solid, (0.180mg, 74% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.16 (d, *J* = 8.12 Hz, 2H), 7.60 (d, *J* = 8.08 Hz, 2H), 7.51-7.31 (m, 2H), 7.03 (d, *J* = 6.96 Hz, 1H), 2.42 (s, 3H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 149.8, 141.9, 135.3, 134.3, 132.1, 129.2, 129.0, 128.0, 123.5, 118.6, 111.1, 21.3.

5-methyl-2-(thiophen-2-yl)-1H-benzo[d]imidazole (5o).²⁴

White solid, (0.148mg, 69% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.79 (s, 1H), 7.81 (d, *J* = 3.24 Hz, 1H), 7.69 (d, *J* = 4.8 Hz, 1H), 7.47-7.29 (m, 2H), 7.21 (t, *J* = 4.72 Hz, 1H), 7.01 (s, 1H), 2.41 (s, 3H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 146.6, 141.7, 135.0, 133.9, 132.0, 128.4, 128.2, 126.4, 123.3, 118.1, 110.8, 21.3.

5,6-dichloro-2-(4-methoxyphenyl)-1H-benzo[d]imidazole (5p).³²

White solid, (0.223mg, 76% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.07 (s, 1H), 8.09 (d, *J* = 8.84 Hz, 2H), 7.78 (s, 2H), 7.11 (d, *J* = 8.88 Hz, 2H), 3.83 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 161.1, 154.0, 128.4, 124.1, 121.8, 114.5, 55.4.

5,6-dimethyl-2-(pyridin-2-yl)-1H-benzo[d]imidazole (5q).³³

Orange solid, (0.194mg, 87% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.85 (s, 1H), 8.68 (d, *J* = 4.68 Hz, 1H), 8.28 (d, *J* = 7.92 Hz, 1H), 7.96 (dt, *J* = 7.56 Hz, 1.52 Hz 1H), 7.46 (t, *J* = 6.16 Hz, 2H), 7.31 (s, 1H), 2.31 (s, 6H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 149.9, 149.3, 148.8, 142.6, 137.4, 133.5, 132.0, 130.3, 124.4, 121.2, 119.2, 112.0, 20.1, 20.1.

2-heptyl-1H-benzo[d]imidazole (5r).^{18b}

White solid, (0.076mg, 35% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.48-7.46 (m, 2H), 7.17-7.11 (m, 2H), 2.88 (t, *J* = 7.8 Hz, 2H), 1.82-1.74 (m, 2H), 1.30-1.22 (m, 2H), 1.20-1.11 (m, 6H), 0.74 (t, *J* = 7.08

Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 155.8, 138.7, 122.2, 114.7, 31.8, 29.5, 29.4, 29.1, 28.5, 22.7, 14.1.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website

Copies of the ¹H NMR, ¹³C NMR of all the compounds and HRMS, IR and crystallographic data of **1**. MS analysis of the crude reaction mixture of *o*-phenylenediamine and 4-methoxybenzyl alcohol (PDF)

X-ray crystallographic data (CCDC 1831616) for **1** (CIF)

AUTHOR INFORMATION

Corresponding Author

*E-mail: dsrimani@iitg.ernet.in

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENT

Financial support from SERB, DST (ECR/2016/000108) and DST-INSPIRE (IFA-14-CH-143) are gratefully acknowledged. We would also like to thank CIF and the Department of Chemistry, IIT-Guwahati, for the instrumental facilities, infrastructural support and startup grant. K.D and A.M are thankful to the institute for their fellowship.

REFERENCES

- (a) Townsend, L. B.; Revankar, G. R. Benzimidazole Nucleosides, Nucleotides, and Related Derivatives. *Chem. Rev.* **1970**, *70*, 389-438. (b) Bhattacharya, S.; Chaudhuri, P. Medical Implications of Benzimidazole Derivatives as Drugs Designed for Targeting DNA and DNA Associated Processes. *Curr. Med. Chem.* **2008**, *15*, 1762-1777.
- Nakano, H.; Inoue, T.; Kawasaki, N.; Miyataka, H.; Matsumoto, H.; Taguchi, T.; Inagaki, N.; Nagai, H.; Satoh, T. Synthesis and Biological Activities of Novel Antiallergic Agents with 5-Lipoxygenase Inhibiting Action. *Bioorg. Med. Chem.* **2000**, *8*, 373-380.
- Iemura, R.; Kawashima, T.; Fukuda, T.; Ito, K.; Tsukamoto, G. Synthesis of 2-(4-substituted-1-piperazinyl)benzimidazoles as H1-Antihistaminic Agents. *J. Med. Chem.* **1986**, *29*, 1178-1183.
- (a) Scott, L. J.; Dunn, C. J.; Mallarkey, G.; Sharpe, M. Esomeprazole: A Review of its use in the Management of Acid-related Disorders. *Drugs* **2002**, *62*, 1503-1538. (b) Yadav, G.; Ganguly, S. Structure Activity Relationship (SAR) Study of Benzimidazole Scaffold for Different Biological Activities: A Mini-review. *Eur. J. Med. Chem.* **2015**, *97*, 419-443.
- Vasiliou, S. Azilsartan Medoxomil for the Treatment of Hypertension. *Drugs Today* **2011**, *47*, 647-651.
- Cohn, G. Zur Kenntniss Des *o*-Amidophenetidens. *Ber.* **1899**, *32*, 2239-2242.
- Morningstar, M. L.; Roth, T.; Farnsworth, D. W.; Smith, M. K.; Watson, K.; Buckheit, R. W.; Das, J. K.; Zhang, W.; Arnold, E.; Ulias, J. G.; Hughes, J. S. H.; Michejda, C. J. Synthesis, Biological Activity, and Crystal Structure of Potent Nonnucleoside Inhibitors of HIV-1 Reverse Transcriptase That Retain Activity against Mutant Forms of the Enzyme. *J. Med. Chem.* **2007**, *50*, 4003-4015.
- Zhu, Z.; Lippa, B.; Drach, J. C.; Townsend, L. B. Design, Synthesis, and Biological Evaluation of Tricyclic Nucleosides (Dimensional Probes) as Analogues of Certain Antiviral Polyhalogenated Benzimidazole Ribonucleosides. *J. Med. Chem.* **2000**, *43*, 2430-2437.
- (a) Panda, S. S.; Malik, R.; Jain, S. C. Synthetic Approaches to 2-Arylbenzimidazoles: A Review. *Curr. Org. Chem.* **2012**, *16*, 1905-1919. (b) Preston, P. N.; Chemistry of Heterocyclic Compounds;

Weissberger, A.; Taylor (Eds.), E. C.; *John Wiley and Sons*: New York **1981**; vol. 40

(10) (a) Stephens, F. F.; Bower, J. D. The Preparation of Benzimidazoles, etc. Part I. *J. Chem. Soc.* **1949**, 2971-2972. (b) Chen, Y. X.; Qian, L. F.; Zhang, W.; Han, B.; Efficient Aerobic Oxidative Synthesis of 2-Substituted Benzoxazoles, Benzothiazoles, and Benzimidazoles Catalyzed by 4-Methoxy-TEMPO. *Angew. Chem., Int. Ed.* **2008**, *47*, 9330-9333. (c) Beaulieu, P. L.; Hache, B.; von Moos, E. A Practical Oxone-Mediated, High-Throughput, Solution-Phase Synthesis of Benzimidazoles from 1,2-Phenylenediamines and Aldehydes and its Application to Preparative Scale Synthesis. *Synthesis* **2003**, *11*, 1683-1692. (d) Bahrami, K.; Khodaei, M. M.; Kavianinia, I. A Simple and Efficient One-Pot Synthesis of 2-Substituted Benzimidazoles. *Synthesis* **2007**, 547-550.

(11) Anastasiou, D.; Campi, E. M.; Chaouk, H.; Jackson, W. R. Synthesis of Benzimidazoles Containing a Fused Alicyclic Ring By Rhodium-Catalysed Hydroformylation of N-Alkenyl-1,2-diaminobenzenes. *Tetrahedron* **1992**, *48*, 7467-7478.

(12) Perry, R. J.; Wilson, B. D. A Novel Palladium-Catalyzed Synthesis of 2-Arylbenzimidazoles. *J. Org. Chem.* **1993**, *58*, 7016-7021.

(13) Brain, C. T.; Brunton, S. A. An Intramolecular Palladium-catalysed Aryl Amination Reaction to Produce Benzimidazoles. *Tetrahedron Lett.* **2002**, *43*, 1893-1895.

(14) Yang, D.; Fokas, D.; Li, J.; Yu, L.; Baldino, C. M. A Versatile Method for the Synthesis of Benzimidazoles from o-Nitroanilines and Aldehydes in One Step via a Reductive Cyclization. *Synthesis* **2005**, 47-56.

(15) (a) Michlik, S.; Kempe, R. A Sustainable Catalytic Pyrrole Synthesis. *Nat. Chem.* **2013**, *5*, 140-144. (b) Srimani, D.; Ben-David, Y.; Milstein, D. Direct Synthesis of Pyrroles by Dehydrogenative Coupling of β -Aminoalcohols with Secondary Alcohols Catalyzed by Ruthenium Pincer Complexes. *Angew. Chem., Int. Ed.* **2013**, *52*, 4012-4015. (c) Zhang, M.; Fang, X. J.; Neumann, H.; Beller, M. General and Regioselective Synthesis of Pyrroles via Ruthenium-Catalyzed Multicomponent Reactions. *J. Am. Chem. Soc.* **2013**, *135*, 11384-11388.

(16) Barta, K.; Ford, P. C. Catalytic Conversion of Nonfood Woody Biomass Solids to Organic Liquids. *Acc. Chem. Res.* **2014**, *47*, 1503-1512.

(17) (a) Chebolu, R.; Kommi, D. N.; Kumar, D.; Bollineni, N.; Chakraborti, A. K. Hydrogen-Bond-Driven Electrophilic Activation for Selectivity Control: Scope and Limitations of Fluorous Alcohol-Promoted Selective Formation of 1,2-Disubstituted Benzimidazoles and Mechanistic Insight for Rationale of Selectivity. *J. Org. Chem.* **2012**, *77*, 10158-10167. (b) Guru, M. M.; Ali, M. A.; Punniyamurthy, T. Copper-Mediated Synthesis of Substituted 2-Aryl-Nbenzylbenzimidazoles and 2-Arylbenzoxazoles via C-H Functionalization C-N/C-O Bond Formation. *J. Org. Chem.* **2011**, *76*, 5295-5308. (c) Shi, X.; Guo, J.; Liu, J.; Ye, M.; Xu, Q. Unexpectedly Simple Synthesis of Benzazoles by tBuONa-Catalyzed Direct Aerobic Oxidative Cyclocondensation of o-Thio/Hydroxy/Aminoanilines with Alcohols under Air. *Chem.-Eur. J.* **2015**, *21*, 9988-9993. (d) Mukhopadhyay, C.; Datta, A.; Butcher, R. J.; Paul, B. K.; Guchhait, N.; Singha, R. Water Mediated Expeditions and Highly Selective Synthesis of 2-Aryl-1-arylmethyl-1H-benzimidazoles by Dowex 50W: Fluorescence Properties of Some Representative Compounds. *Arkivoc* **2009**, *xiii*, 1-22. (e) Kumar, D.; Kommi, D. N.; Chebolu, R.; Garg, S. K.; Kumar, R.; Chakraborti, A. K. Selectivity Control During the Solid Supported Protic Acids Catalyzed Synthesis of 1,2-disubstituted Benzimidazoles and Mechanistic Insight to Rationalize Selectivity. *RSC Adv.* **2013**, *3*, 91-98. (f) Xu, Z.; Wang, D.; Yu, X.; Yang, Y.; Wang, D. Tunable Triazole-Phosphine-Copper Catalysts for the Synthesis of 2-Aryl-1H-benzod[*j*]imidazoles from Benzyl Alcohols and Diamines by Acceptorless Dehydrogenation and Borrowing Hydrogen Reactions. *Adv. Synth. Catal.* **2017**, *359*, 3332-3340.

(18) (a) Kondo, T.; Yang, S.; Huh, K.; Kobayashi, M.; Kotachi, S.; Watanabe, Y. Ruthenium Complex-catalyzed Facile Synthesis of 2-substituted Benzo-azoles. *Chem. Lett.* **1991**, *20*, 1275-1278. (b) Hille, T.; Irrgang, T.; Kempe, R. The Synthesis of Benzimidazoles and Quinoxalines from Aromatic Diamines and Alcohols by Iridium-Catalyzed Acceptorless Dehydrogenative Alkylation. *Chem. Eur. J.* **2014**, *20*, 5569-5572. (c) Sharma, A. K.; Joshi, H.; Bhaskar, R.; Singh, A. K.

Complexes of (η^5 -Cp*)Ir(III) with 1-Benzyl-3-phenylthio/Selenomethyl-1,3 dihydrobenzimidazole-2-thione/Selenone: Catalyst for Oxidation and 1,2-Substituted Benzimidazole Synthesis. *Dalton Trans.* **2017**, *46*, 2228-2237.

(19) (a) Zell, T.; Milstein, D. Hydrogenation and Dehydrogenation Iron Pincer Catalysts Capable of Metal-Ligand Cooperation by Aromatization/De aromatization. *Acc. Chem. Res.* **2015**, *48*, 1979-1994. (b) Kallmeier, F.; Kempe, R. Manganese Complexes for (De)Hydrogenation Catalysis: A Comparison to Cobalt and Iron Catalysts. *Angew. Chem., Int. Ed.* **2018**, *57*, 46-60. (c) Srimani, D.; Diskin-Posner, Y.; Ben-David, Y.; Milstein, D. Iron Pincer Complex Catalyzed, Environmentally Benign, E-Selective Semi-Hydrogenation of Alkynes. *Angew. Chem., Int. Ed.* **2013**, *52*, 14131-14134.

(20) (a) Mukherjee, A.; Nerush, A.; Leitus, G.; Shimon, L. J. W.; Ben-David, Y.; Jalapa, N. A. E.; Milstein, D. Manganese-Catalyzed Environmentally Benign Dehydrogenative Coupling of Alcohols and Amines to Form Aldimines and H₂: A Catalytic and Mechanistic Study. *J. Am. Chem. Soc.* **2016**, *138*, 4298-4301. (b) Elangovan, S.; Neumann, J.; Sortais, J. P.; Junge, K.; Darcel, C.; Beller, M. Efficient and Selective N-alkylation of Amines with Alcohols Catalyzed by Manganese Pincer Complexes. *Nat. Commun.* **2016**, *7*, 12641. (c) Mastalir, M.; Glatz, M.; Gorgas, N.; Stöger, B.; Pittenauer, E.; Allmaier, G.; Veiros, L. F.; Kirchner, K. Divergent Coupling of Alcohols and Amines Catalyzed by Isoelectronic Hydride MnI and Fe(II) PNP Pincer Complexes. *Chem. Eur. J.* **2016**, *22*, 12316-12320. (d) Kallmeier, F.; Irrgang, T.; Dietel, T.; Kempe, R. Highly Active and Selective Manganese C=O Bond Hydrogenation Catalysts: The Importance of the Multidentate Ligand, the Ancillary Ligands, and the Oxidation State. *Angew. Chem., Int. Ed.* **2016**, *55*, 11806-11809. (e) Elangovan, S.; Topf, C.; Fischer, S.; Jiao, H.; Spannenberg, A.; Baumann, W.; Ludwig, R.; Junge, K.; Beller, M. Selective Catalytic Hydrogenations of Nitriles, Ketones, and Aldehydes by Well-Defined Manganese Pincer Complexes. *J. Am. Chem. Soc.* **2016**, *136*, 8809-8814. (f) Deibl, N.; Kempe, R. Manganese-Catalyzed Multicomponent Synthesis of Pyrimidines from Alcohols and Amidines. *Angew. Chem., Int. Ed.* **2017**, *56*, 1663-1666. (g) Mastalir, M.; Glatz, M.; Pittenauer, E.; Allmaier, G.; Kirchner, K. Sustainable Synthesis of Quinolines and Pyrimidines Catalyzed by Manganese PNP Pincer Complexes. *J. Am. Chem. Soc.* **2016**, *138*, 15543-15546. (h) Peña-López, M.; Piehl, P.; Elangovan, S.; Neumann, H.; Beller, M. Manganese-Catalyzed Hydrogen-Autotransfer C-C Bond Formation: α -Alkylation of Ketones with Primary Alcohols. *Angew. Chem., Int. Ed.* **2016**, *55*, 14967-14971.

(21) (a) Nguyen, D.; Trivelli, X.; Capet, F.; Paul, J.; Dumeignil, F.; Gauvin, R. M. Manganese Pincer Complexes for the Base-Free, Acceptorless Dehydrogenative Coupling of Alcohols to Esters: Development, Scope, and Understanding. *ACS Catal.* **2017**, *7*, 2022-2032. (b) Dubey, A.; Nencini, L.; Fayzullin, R. R.; Nervi, C.; Khusnutdinova, J. R. Bio-Inspired Mn(I) Complexes for the Hydrogenation of CO₂ to Formate and Formamide. *ACS Catal.* **2017**, *7*, 3864-3868. (c) Kallmeier, F.; Dudzic, B.; Irrgang, T.; Kempe, R. Manganese-Catalyzed Sustainable Synthesis of Pyrroles from Alcohols and Amino Alcohols. *Angew. Chem., Int. Ed.* **2017**, *56*, 7261-7265. (d) Chakraborty, S.; Kumar Das, U.; Ben-David, Y.; Milstein, D. Manganese Catalyzed α -Olefination of Nitriles by Primary Alcohols. *J. Am. Chem. Soc.* **2017**, *139*, 11710-11713. (e) Brzozowska, A.; Azofra, L. M.; Zubar, V.; Atodiresei, I.; Cavallo, L.; Rueping, M.; El-Sepelgy, O. Highly Chemo- and Stereoselective Transfer Semihydrogenation of Alkynes Catalyzed by a Stable, Well-Defined Manganese(II) Complex. *ACS Catal.* **2018**, *8*, 4103-4109 and the references cited therein.

(22) Daw, P.; Ben-David, Y.; Milstein, D. Direct Synthesis of Benzimidazoles by Dehydrogenative Coupling of Aromatic Diamines and Alcohols Catalyzed by Cobalt. *ACS Catal.* **2017**, *7*, 7456-7460.

(23) Mehtab, A.; Thakera, A.; Londhe, V.; Nandana, S. R. Reinvestigating Raney Nickel Mediated Selective Alkylation of Amines with Alcohols via Hydrogen Autotransfer Methodology. *Applied Catalysis A: General* **2014**, *478*, 241-251.

(24) Puylaert, P.; Van Heck, R.; Fan, Y.; Spannenberg, A.; Baumann, W.; Beller, M.; Medlock, J.; Bonrath, W.; Lefort, L.; Hinze, S.; de Vries, J. G. Selective Hydrogenation of α,β -Unsaturated Aldehydes and Ketones by Air-Stable Ruthenium NNS Complexes. *Chem. Eur. J.* **2017**, *23*, 8473-8481.

1 (25) Broad signal in the ^1H nmr of Mn(I) complex was described by
2 Beller and coworkers Perez, M.; Elangovan S.; Spannenberg, A.;
3 Junge, K.; Beller, M. *ChemSusChem* **2017**, *10*, 83–86.

4 (26) Ghosh, P.; Mandal, A. Synthesis of Functionalized Benzimid-
5 azoles and Quinoxalines Catalyzed by Sodium Hexafluorophosphate
6 Bound Amberlite Resin in Aqueous Medium. *Tetrahedron Lett.* **2012**,
7 *53*, 6483-6488.

8 (27) Dabiri, M.; Salehi, P.; Baghbanzadeh, M.; Nikcheh, M. S. Wa-
9 ter-Accelerated Selective Synthesis of 1,2-Disubstituted benzimidaz-
10 oles at Room Temperature Catalyzed by Brønsted Acidic Ionic Liquid
11 *Synth. Commun.* **2008**, *38*, 4272-4281.

12 (28) Mohammadi, A. A.; Azizian, J.; Karimi, N. Caro's Acid-Silica
13 Gel Catalyzed Synthesis of 2-Aryl-1H-Benzimidazoles and 2-Aryl-1-
14 arylmethyl-1H-benzimidazoles. *Heterocycles* **2009**, *78*, 2337-2342.

15 (29) Geiger, D. K.; DeStefano, M. R. 5,6-Dimethyl-2-(pyridin-2-yl)-
16 1-[(pyridin-2-yl)methyl]-1H-benzimidazole. *Acta Cryst.* **2014**, *E70*,
17 o365.

18 (30) Schiffmann, R.; Neugebauer, A.; Klein, C. D. Metal-Mediated
19 Inhibition of Escherichia coli Methionine Aminopeptidase: Structure-
20 Activity Relationships and Development of a Novel Scoring Function
21 for Metal-Ligand Interactions. *J. Med. Chem.* **2006**, *49*, 511-522.

22 (31) Mobinikhaledi, A.; Forughifar, N.; Zendehtel, M.; Jabbarpour,
23 M. Conversion of Aldehydes to Benzimidazoles using NaY Zeolite.
24 *Synthesis and Reactivity in Inorganic, Metal-Organic, and Nano-Metal*
25 *Chemistry*, **2008**, *38*, 390-393.

26 (32) Mukhopadhyay, C.; Tapaswi, P. K.; Dowex 50W: A Highly Ef-
27 ficient and Recyclable Green Catalyst for the Construction of the 2-
28 Substituted Benzimidazole Moiety in Aqueous Medium. *Catal. Com-*
29 *mun.* **2008**, *9*, 2392-2394.

30 (33) Subran, K. S.; Banjerjee, S.; Mondal A.; Paira, P. Amberlite IR-
31 120(H)-mediated "On Water" Synthesis of Novel Anticancer Ruthe-
32 nium(II)-p-cymene 2-Pyridinylbenzothiazole (BTZ), 2-Pyridinylben-
33 zoxazole (BOZ) & 2-Pyridinylbenzimidazole (BIZ) Scaffolds. *New J.*
34 *Chem.*, **2016**, *40*, 10333-1034